April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post

April 20, 2026

Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC

Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C...

The ASCO Post

April 14, 2026

Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC

Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findin...

The ASCO Post

April 14, 2026

Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment

“This randomized phase II study demonstrated that 30 Gy in one fraction was equivalent to 60 Gy in three fractions in terms of toxicity, local failure, freedom from distal failure, progression-free su...

The ASCO Post

April 07, 2026

Two Major Cancer Centers Announce Appointments of New Directors

Last week, Dartmouth Cancer Center and Fox Chase Cancer Center announced the appointments of new directors—both experts in the treatment of lung cancer.

The ASCO Post

March 15, 2026

Dana-Farber Research News 04.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 - 15.

Dana-Farber

March 06, 2026

When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key

Researchers at Dana-Farber Cancer Institute have uncovered why small cell lung cancer (SCLC) can stay largely out of reach of the immune system, even when the cancer cells themselves are vulnerable to immune attack.

Dana-Farber

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post

February 08, 2023

Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC

In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been as...

The ASCO Post

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post